Roflumilast Added to Antipsychotic Medication for Thinking Difficulties in Schizophrenia
About this title
Read the official source — NCT02079844Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
- Listed locations
- Denmark HillSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 20
- Sponsor
- Takeda
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United Kingdom
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT02079844
- Official title
Show the full official title
A Randomized, Double-Blind, Placebo Controlled, 3-period, Proof of Mechanism, Cross-Over Study of Roflumilast Administered up to Steady State to Evaluate the Effects of Add-on Roflumilast to Second Generation Antipsychotics on Cognitive Impairment as Well as Brain Imaging (ie, fMRI) and Electrical Activity (ie, EEG) Changes Observed in Subjects With Stable Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Denmark Hill
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Takeda.
Did this study involve medication?
Yes. The study involved medication, including Roflumilast, Placebo and Second generation antipsychotic.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
